I n the past 50 yrs, critical care has evolved from a discipline present in few institutions to a widely prevalent specialty (1, 2) . This rapid growth has been accompanied with an increased understanding of the pathophysiology of critical illness. For example, many of the laboratory advances in the understanding of sepsis and acute lung injury have led to clinical trials. In addition, a number of national and international critical care trial groups (Canadian Critical Care Trials Group, www.ccctg.ca; the Australian and New Zealand Intensive Care Society; German Competence Network Sepsis; the United States National Institutes of Health ARDS Network, www.ardsnet.org; the United States Critical Illness and Injury Trials Group, www.massgeneral.org/research/ researchlab.aspx?idϭ1262) have been cre-ated to better understand the natural history of critical illness and to enhance current therapies and advance new treatments for critically ill patients.
Critical care trials present special challenges. For example, many illnesses that prompt intensive care unit (ICU) admission are syndromes rather than diseases and thus suffer from heterogeneity between patients and lack a biological diagnostic test ("biomarker") to facilitate early identification of patients for interventions. Additionally, the short time window and the frequent requirement to obtain surrogate (third-party) consent leads to a relatively low ratio of screened to enrolled patients, raising concerns about the generalization of completed clinical trials in routine clinical practice (external validity). In raising such concerns ourselves, we use recent examples from the critical care literature. A recent supplement in this journal addressed in-depth issues regarding trial design that may be of particular interest to critical care researchers (3) . We have divided this review into sections discussing trial design, selection of experimental subjects and controls, outcome measures, bias, sample size calculation, and interpretation of results that highlight specific trial design concepts that have implications for understanding the natural history of critical illness and the results from recent clinical trials. This review is intended to highlight important trial design features and inter-pretation concepts so that bedside clinicians may, in conjunction with their experience and training, better evaluate whether to provide a specific therapy tested in a clinical trial to a specific patient.
Study Design
Clinical studies are generally divided into two primary groups according to study design: observational and experimental studies. Observational studies include case-control, cross-sectional, and cohort studies. In contrast, the randomized, controlled clinical trial is the archetypal example of an experimental study. The primary difference between these two designs is that observational trials "observe" the results of exposures or interventions in study subjects as a method to ascertain associations between these exposures and an outcome of interest, whereas experimental studies assign subjects to an exposure or intervention and prospectively evaluate its effect on an outcome of interest. Participants enrolled into experimental trials are often more highly selected than participants enrolled into observational trials (4) .
Case-Control Studies
Case-control studies ( Fig. 1 ) involve identification of study subjects with (cases) and without (controls) an outcome of interest and then retrospective Objective: Better understanding of the pathophysiology of critical illness has led to an increase in clinical trials designed to improve the clinical care and outcomes of patients with lifethreatening illness. Knowledge of basic principles of clinical trial design and interpretation will assist the clinician in better applying the results of these studies into clinical practice.
Data Sources: We review selected clinical trials to highlight important design features that will improve understanding of the results of critical care clinical trials designed to improve clinical care of the critically ill.
Results: Trial design features such as patient selection, bias, sample size calculation, selection of subjects and controls, and primary outcome measure may influence the results of a critical care clinical trial designed to test a therapy targeting improved clinical care. In conjunction with trial design knowledge, understanding the size of the anticipated treatment effect, the importance of any clinical end point achieved, and whether patients in the trial are representative of typical patients with the illness will assist the reader in determining whether the results should be applied to specific patients or usual clinical practice.
Conclusions: Better understanding of important aspects of trial design and interpretation, such as whether patients enrolled in both intervention arms were comparable and whether the primary outcome of the trial is clinically important, will assist the bedside clinician in determining whether to apply the findings from the clinical study into clinical practice. (Crit Care Med 2010; 38: 1882-1889) KEY WORDS: clinical trial; critical care; adult; outcomes examination of the potential exposures or interventions (predictor variables) associated with the outcome of interest (5) .
Case-control studies are the most efficient study design for rare diseases or infrequent outcomes, but they are subject to multiple potential biases, can examine only one chosen outcome, and are at high risk for the influence of confounding variables (5) . Confounding occurs when a third factor is associated with both the exposure or intervention and the outcome of interest. A confounder may distort the relationship between the exposure and outcome undergoing study. For example, in a casecontrol study examining the costs of methicillin-resistant Staphylococcus aureus infection in the ICU, matching between cases and controls was performed for age, comorbidity, severity of illness, and the number of organ failures (6) . Despite these adjustments, other factors may differ between those patients with nosocomial methicillin-resistant Staphylococcus aureus infections and those without, such as operative intervention, duration of ICU stay, and immune function, among other variables that were not considered in this study (6) . Any of these variables may be a confounder because any of them might be present more frequently in one group than the other and could reasonably be associated with the presence of methicillin-resistant Staphylococcus aureus.
Cohort Studies
Cohort studies may be undertaken to describe the occurrence of certain out-comes or to analyze associations between exposures (predictors) and outcomes (5) . Prospective cohort studies ( Fig. 2A ) involve selection of a group of study subjects for enrollment, collection of data regarding exposures (predictor variables), and then observation of the subjects over time with standardized assessment of outcomes. Retrospective cohort studies ( Fig. 2B ) start with selection of a group of subjects, but in this case, selection is from a historical or theoretical group of patients who existed in the past, and then data on both exposures and outcomes are collected. Both prospective and retrospective cohort studies are subject to potential confounding and have limitations in assigning causality in the observed associations between exposure and outcome (5, 7) . Prospective cohorts have the ability to determine temporal relationships between exposure and outcome, whereas retrospective studies are more time-efficient and resourceefficient. For example, a prospective cohort study sought to determine longterm outcomes after acute respiratory distress syndrome (ARDS) and thus identified a cohort of ARDS survivors in hospital who were then prospectively evaluated at 3, 6, and 12 mos after ICU discharge (8) . Despite limitations in sample size, a single geographic location, and heterogeneity among ARDS survivors, the authors identified predictors of physical function limitations at 1 yr after ICU discharge, which may provide important information to inform future studies and clinical care.
Randomized Controlled Trials
Randomized clinical trials are the best study design for measuring the efficacy of an intervention in causing the outcome of interest (7, 9, 10) . The use of random allocation of study subjects has the potential to substantially reduce or theoretically eliminate confounding by randomly distributing all known and unknown predictor variables, except the intervention being tested, evenly between the intervention and control groups. In a randomized clinical trial ( Fig. 3) , study subjects are selected prospectively according to eligibility criteria and, after informed consent, they are randomly allocated to an intervention or control group (5) . Blinding, or masking, is critical in clinical trials to prevent bias in application of the randomized intervention or cointerventions, or assessment of the relevant outcomes, particularly when the outcomes are subjective (10) . Blinding is important; if the outcome measured is subjective, then there is a possibility that the investigators may consciously or unconsciously use different cointerventions if they are aware of the intervention (5, 10) . Some critical care interventions, such as a device trial (use of high-frequency oscillation vs. conventional mechanical ventilation), do not lend themselves to blinding (11) .
For interventions that may be relevant to a single patient population but do not overlap or interfere with each other, factorial randomization may be used to test both interventions in a single study (10) . Factorial randomization allows the testing of two (or more) interventions by randomizing patients sequentially for each tested intervention. The factorial design not only allows for testing of multiple interventions in a single study but also allows for the examination of interaction effects. For example, in acute lung injury patients, the ARDS Network compared outcomes with pulmonary artery catheterization vs. central venous catheterization and also compared a fluid liberal vs. a fluid conservative strategy (12, 13) . In this trial, the investigators reported no difference based on catheter randomization but a significant benefit in the fluid conservative vs. fluid liberal management group (12, 13) . Similar study designs using factorial randomization have reported significant differences in both randomized interventions, such as when comparing intravenous fluid solutions (crystalloids vs. starch solutions) along with glucose control (intensive vs. conventional insulin management) (14) . The primary advantage of a clinical trial, stronger evidence for a cause-effect relationship for the intervention and outcome, is balanced against the greater cost, complexity, and time required for study completion (7) . In addition, interventions in which physicians lack equipoise or uncertainty about the effect of the intervention cannot be tested in a randomized trial (15, 16) .
Randomized controlled trials generally rank more highly in terms of ability to draw valid causal inferences regarding the intervention and the outcome (7, 10, 17). One example that illustrates the advantages of randomized controlled trials is the publication of a cohort study asserting an increased risk of death with the use of pulmonary artery catheterization in critically ill patients (18). At the time, clinicians lacked equipoise to permit an effective randomized study of pul-monary artery catheterization (19). However, after the publication of this cohort study, physician investigators were able to complete several randomized clinical trials to determine the effect of pulmonary artery catheters on clinical outcomes (12, 20, 21) . It is noteworthy that the findings of an increased risk of death in observational studies were not confirmed in these subsequent randomized clinical trials, a conflicting result between observational studies and randomized trials that occurs up to 33% of the time (22). In Table 1 , we summarize pros and cons of observational vs. controlled trials.
Selection of Experimental Subjects and Controls
The designation and identification of the desired participant (critically ill patient) for enrollment is a crucial part of most trial designs. Ideally, the study investigators want to select the patient who would benefit most from a planned intervention. The importance of understanding the most appropriate patients for enrollment is highlighted by the publication of two clinical trials testing the use of glucocorticoids in septic shock patients. Annane et al (23) tested the use of corticosteroids in patients with a systolic pressure of Ͻ90 mm Hg despite fluid resuscitation and vasopressor therapy. The CORTICUS trial enrolled patients who had a systolic pressure of Ͻ90 mm Hg or the need for vasopressor therapy after volume resuscitation (24). Thus, the patients enrolled in the two studies may have been chosen from different patient populations: one with refractory shock and the other without refractory shock (23, 24). Although there were other differences between the two studies, it is possible that the differing effect of glucocorticoids on mortality observed in these two studies may be related to differences in the severity of septic shock of the patients enrolled.
In controlled studies, an intervention is compared against a standard care group. To properly assess the effect of the intervention, the group chosen as standard or usual care should fit within the confines of current practice. Although this concept may be simple in theory, the wide variation of critical care treatment between sites may make this challenging (25).
Figure 2.
Illustration of a prospective and retrospective cohort study. A, In a prospective cohort study, at the outset of the study, the investigator selects a sample from the population and measures the exposures of interest (shaded areas) before following up the patients over time to determine the occurrence of relevant outcomes and their association with the exposures (following the dark forward arrow). B, In a retrospective cohort study, at the outset of the study, the investigator identifies a cohort of subjects that existed in the past, assesses exposure retrospectively from that group (shaded areas), and then assesses the relevant outcomes in the present or at a defined future point (dark forward arrow).
Figure 3.
Illustration of a randomized controlled trial. In a randomized, controlled clinical trial, the investigator identifies a group of eligible subjects (dotted circle) from an appropriate patient population (hashed circle) and then applies the defined inclusion and exclusion criteria to enroll subjects. At the start of the study, the investigator measures baseline variables and randomly allocates subjects to intervention groups ("treatment" in gray, or "control"). Outcomes are measured prospectively during the follow-up period. Ideally, allocation, intervention, and outcome assessment should be blinded.
Outcome Measures: Surrogate End Points
Critical care trials are difficult and expensive to implement. One way to limit both the expense and the scope of a clinical trial is to pick an easily measured end point that is associated with the outcome of interest. Whereas death is often used as the "gold standard" clinical outcome, it may not be feasible to design a small, exploratory trial that will show a statistically significant mortality benefit. Surrogate outcome measures may be chosen because fewer patients are required to show a treatment effect, leading to a simpler and less expensive trial (9) . A common example of a surrogate end point outside of critical care is the use of CD4 ϩ cell count in clinical trials of antiretroviral therapies. Because many drugs that increase CD4 ϩ counts will also improve mortality rates in patients with human immunodeficiency virus, the use of CD4 ϩ count as a surrogate end point has been widespread (26, 27).
Mean arterial pressure may appear to be a logical surrogate end point for trials of therapies for patients with septic shock. Because patients with septic shock have hypotension as a result of distributive shock, and because therapy for septic shock includes administering drugs to increase systemic blood pressure, there is biological plausibility for the use of mean arterial pressure as a surrogate end point (28). However, a nonspecific nitric oxide synthase inhibitor that effectively increases blood pressure was shown to increase mortality rates in patients with septic shock (29, 30). Thus, at least in these studies, mean arterial pressure was not a useful surrogate marker for patient mortality.
An ideal surrogate outcome marker is causally or pathogenetically related to the disease (and thus to the outcome) and accurately linked with the outcome. Many surrogate outcomes such as mean arterial pressure in septic shock and oxygenation in acute lung injury have been used in critical care (30 -33). Unfortunately, to date no individual surrogate prognostic marker has been found to be sufficiently robust to accurately predict mortality in critically ill subjects (34).
Combined End Points
Combined or composite end points represent another potential method to decrease the number of patients required to show an effect size in critical care trials (35). The use of a combined end point requires that the combined end points be clinically important and of equal importance to the patient, be potentially biologically distinct, and have direct interpretation (10, 35) . Some investigators also advocate that the frequency of occurrence of each component in the combined end point should be similar and should have similar risk reductions in response to an effective intervention (36) . If these conditions are not met, then a composite end point may provide misleading information (36) . One example of a composite end point is the ventilatorfree days score. This score combines the number of days in which a patient is both alive and free from mechanical ventilation over a specific time period, usually 28 days (37, 38) . The use of these combined end points may allow more efficient trials of specific therapies in critically ill patients in which a mortality benefit and a decrease in the number of days of mechanical ventilation among those who are alive is expected. It is important to note that the value of these scores must be placed into the context of the other risks and benefits of effective therapies (35).
Methods for competing risks, if used in the proper setting, may be an adequate alternative to the use of combined end points for the evaluation of interventions in critical care trials (38) . Specifically, mixtures of survival distributions may be particularly useful to model outcomes that are competing and mutually exclusive, such as designs in which participants are followed up until in-hospital death or until unassisted breathing among those who are eventually discharged home alive (38) .
Sample Size Calculation
Determination of sample size is an important aspect of planning for any clinical study, and sample size calculations should be described in detail in any published report (39, 40) . The goal of this section is to provide critical care researchers with an overview to sample size calculations for phase III, randomized controlled trials with two treatment groups and a well-defined, patientcentered clinical end point such as 60-day mortality. Formulae and software to assist with sample size calculation are found elsewhere (9, 10, 41, 42) .
The calculation of sample size for any clinical investigation requires a priori specification of the population, hypotheses undergoing study, and explicit definition of the primary outcome. Hypotheses make statements about a population "parameter," such as the proportion of critically ill patients who died within 60 days. The goal of a hypothesis test is to decide, based on a sample from the population undergoing study, which of the two complementary hypotheses is true (10) . In any clinical investigation, hypothesis testing risks two fundamental errors. First, a single experiment may lead to investigators to believe that two treatments differ when, in fact, they do not, leading to a false-positive result (type 1 error rate, defined as ␣) (5) . Second, a single experiment may lead investigators to believe that two treatments do not differ when, in fact, they do, leading to a false-negative result (type 2 error rate, defined as ␤) (5, 10) .
The factors that contribute to the calculation of sample size when comparing a primary outcome between two interventions include the "test statistic," used to compare a difference in the primary outcome measures between two interventions, and the error rates associated with the hypothesis test (␣ and ␤) (9). The "test statistic" depends on both the expected difference in the primary outcome between two treatment groups and on an estimate of the variance of the primary outcome measure, and it is usually based on data from sets of smaller clinical trials or observational studies or, preferably, obtained from the same institution or hospital centers where the clinical trial is to be conducted (9) . Different assumptions about ␣ and ␤ will have a direct effect on sample size. Ordinarily, the value of ␣ is set at 0.05, but it can be set at a smaller value to decrease the chance of a false-positive result. The value for ␤ is usually set between 0.05 and 0.20 (5, 9, 10) . The complement of ␤ is statistical power (1 Ϫ ␤), which represents the probability of declaring that two interventions are different when they are in fact truly different (5, 10) . Other factors that directly affect sample size include clustering in the responses of participants, as in the case of cluster randomized trials, participant allocation ratios of other than 1:1 to each intervention, early stopping rules, and testing three or more interventions in one trial (41) (42) (43) .
Early stopping rules are intended to protect participants in clinical trials from unsafe interventions, hasten the implementation of beneficial interventions, or to stop trials that are unlikely to show treatment differences between groups. Methods for stopping trials by design have been available for more than 50 years, but recent advances in statistical methodology and better computer software have made these methods more accessible to trialists (44) . In general, an initial sample size still needs to be calculated based on the principles discussed, but the overall sample size calculation is then penalized (increased) by the number of interim analyses planned (45) . Examples of stopping clinical trials by design include the ARDS Network studies, e.g., the lower tidal volume trial stopped early at 861 patients (out of an originally proposed sample size of 1,000) after the fourth interim analysis showed that lower tidal volumes were significantly more beneficial than higher tidal volumes (37) . In general, both a convincing treatment effect and a large number of patients enrolled should be present to stop a trial early (45) . One potential downside of stopping a trial early includes finding an overly large treatment effect (46, 47) .
To illustrate all of these factors in play, we discuss the sample size calculation from the CORTICUS trial (24). In this trial, the investigators calculated that a sample size of 800 participants (400 per group) was needed to achieve a statistical power of 80% (␤ ϭ 0.20) with a maximum overall type 1 error rate of 5% (␣ ϭ 0.05) to detect an absolute decrease in mortality of 10% for an overall expected 28-day mortality of 50% in the control group (24). The overall 28-day mortality in their study population was 33% (164/ 499). Ignoring interim analyses, the expected sample size for a mortality of 33% and a difference of 10% between groups would have been lower at 670 participants (335 per group) (24). The investigators had planned stopping rules in which they penalized the type 1 error rate using the O'Brien-Fleming method as follows: p ϭ .0006 for the first interim analysis, p ϭ .005 for the second interim analysis, and p ϭ .047 for the final analysis (24, 48). However, the trial was administratively stopped with 499 patients enrolled for multiple reasons (24). Despite lower overall 28-day mortality in the treatment group, the investigators were probably still underpowered to detect a mortality difference of 10%.
Internal and External Validity
There are many potential reasons why a clinical trial might show benefit. Whether the treatment is responsible for the clinical benefit underlies the concept of internal validity. The National Institutes of Health ARDS Network low tidal volume trial provides a useful example of a study with good internal validity. To minimize treatment variation, the ventilatory practices used in the study were mandated by protocol, and the coordinating center randomly audited selected ventilator settings for compliance with the protocol. Furthermore, it is important to ensure the use of similar treatment protocols for other relevant interventions associated with the primary outcome across different centers to minimize the risk that an unmeasured or unintended factor was responsible for the differences seen between treatment groups (37) .
Whether study results can be generalized to patients who are not enrolled in the study reflects the concept of external validity. Many critical care trials require the screening of 10 patients for each patient enrolled (13, 49) . Thus, it is unknown whether patients who were not enrolled in these trials because of comorbidities and other reasons would have similar or different responses to the tested interventions compared with enrolled patients (50) .
Bias in Clinical Studies
Bias results from a systematic error in study design or execution leading to differences between study groups (10, 51) . It can generally be divided into two categories: selection bias and information bias. Selection bias refers to an unrecognized difference between treatment and control groups, whereas information bias refers to an incorrect assessment or measurement of exposure, outcome, or both (5, 51) . Selection bias includes errors in choosing the individuals or groups to take part in a scientific study, and sampling bias refers to some members of the population being more likely to be included than others. Information bias includes errors in diagnosis or exposure assessment, including misclassification of the outcome or exposure of interest (51) . If the subjects in one group are misclassified more frequently than the others, then "differential" misclassification may lead to invalid conclusions, whereas nondifferential misclassification increases "noise" and may obscure true results, i.e., bias toward the null hypothesis (5, 51) . Although bias is more common in observational research, even randomized controlled trials may have bias, most often resulting from selection bias related to unconcealed allocation, unblinding, and exclusions after randomization (51) .
Misclassification bias refers to the possibility of incorrectly identifying patients with (or without) an illness (5) . If participants are enrolled into a trial and are more or less likely to be influenced by the therapy, then this will alter the results compared to the "average" patients and their susceptibility. This is particularly challenging for conditions without a perfect diagnosis, such as syndromic conditions like sepsis and acute lung injury, thus making misclassification bias an important consideration in many clinical critical care trials.
One often-cited example of misclassification bias centers on the consensus definition for ARDS. The American European Consensus Definition of ARDS includes four criteria: acute onset, diffuse bilateral infiltrates consistent with pulmonary vascular congestion, PaO 2 / FIO 2 ratio of Յ200, and no evidence of left atrial hypertension (52) . A study of chest radiographs of ARDS patients suggested that there was heterogeneity of opinions among expert clinicians regarding whether a specific radiograph met the criteria for ARDS (53) . In addition, a recent trial examining whether the use of a pulmonary artery catheter improved outcomes in patients with acute lung injury demonstrated that 29% of the patients enrolled into the trial had pulmonary capillary occlusion pressures of Ͼ18 cm H 2 O, and thus potentially could have been excluded from the trial if these results had been available previously (12) .
Interpretation of Results
Several factors will help the reader determine whether the results of a controlled clinical trial are valid and clinically important (37, 54) . First, the reader must determine whether patients enrolled in either intervention arm were comparable. Comparability suggests that randomization worked appropriately. Second, the reader must determine that the primary outcome in the article is clinically important and consistent with that reported in the article methods and a clinical trial registry. A trial that shows an improvement in mortality or in the number of organ failures would obviously be more compelling than one that shows a change in a non-patient-centered outcome such as a laboratory test (54) . There are several ways in which investigators may present the overall effect size of a clinical trial. We summarize the most commonly used measures of effect size when mortality is used as the outcome in Table 2 .
Some clinical trials have shown benefits in specific subgroups of patients but not in the primary patient population (55) (56) (57) (58) . In general, subgroup analyses not defined by design a priori should be avoided, because any postrandomization differences (e.g., bias) will undermine the original randomization assignment. Subgroup analyses may be considered hypothesis generating for an additional study but should not be considered to be practice changing (58 -60) . Finally, the reader should evaluate whether the study population is similar to their population of patients or to those for whom the intervention may be applied (10) .
It is important to distinguish between results that are statistically different and clinically important. For example, in the SAFE trial comparing albumin vs. saline resuscitation, the baseline central venous pressure in the albumin group vs. the saline group was 9.0 Ϯ 4.7 vs. 8.6 Ϯ 4.6 mm Hg, a difference that was statistically different but probably not clinically important (61) . In critical care clinical trials, a clinically relevant and objective end point, such as mortality, is likely to garner more attention than a more subjective end point (10, 54) . In addition, information about the size of the treatment effect is also important in determining whether a trial result should change practice (62) . Other factors that may influence whether a trial should change practice include whether the trial is multicenter, has an adequate sample size, and is repeated with similar results (63) (64) (65) .
Novel Designs That May Prove Useful for Critical Care Trials
Given the complexity of critical care trials and the difficulty and expense of reaching a mortality end point (66, 67) , adaptive trial design techniques have been used in some clinical trials (68, 69) to streamline selection of an effective intervention. One example of a trial with a sequential trial design was the recently numbers needed to harm; the number of patients who need to be treated to prevent a death (numbers needed to treat) or for whom treatment will result in death (numbers needed to harm); the higher the numbers needed to treat (or numbers needed to harm), the less effective (or less harmful) is the experimental approach completed trial of norepinephrine vs. dopamine for patients with shock (70) . Some of the limitations of designs like "play the winner" are that they may lead to an increased possibility of a falsepositive trial (falsely rejecting the null hypothesis). Other novel ideas that may prove useful in future critical care trials include the idea of personalizing therapy based on novel strategies that include genomics, proteonomics, or pharmacogenomics. Whereas the concept of identifying patients who might be best served by prescription of a specific medication or treatment is quite attractive (71, 72) in patients with sepsis or acute lung injury, attempts to identify biomarkers upon which decision to give therapy might be based have not yet delivered (50, 73) .
CONCLUSION
Critically ill patients present unique challenges to the investigator charged with testing a new therapy. An understanding of the important basic concepts of trial design and interpretation will assist the critical care clinician in deciding whether the results of a critical care clinical trial are valid and relevant to the patient in front of them. The size of the trial, the treatment effect in relation to potential adverse events, and the patient population enrolled should help the clinician determine whether to choose a particular therapy for a specific patient based on a clinical trial. of randomized controlled trials fails, but needn't. 
